MAHUA OIL CONTAINING SUPPOSITORY BASE EXHIBITED HIGHER DRUG RELEASE AS COMPARED TO COCOA BUTTER BASE

The present research aimed at scrutinizing the role of Mahua Oil (MO) as a suppository base which can enhance the release of drug in the site of administration. Three formulations were designed with erythromycin as the drug utilizing; F1 (MO and Beeswax in the ratio of 3:1), F2 (MO and PEG 6000 in the ratio of 1:1), and F3 (cocoa butter – 100%) as the base material. The suppositories were prepared using pour molding method after suitable calibration of molds. All the formulations were characterized in terms of breaking strength, disintegration time, drug content, in-vitro dissolution, and accelerated stability studies. The MO containing formulations displayed a good breaking strength, optimized disintegration time, and higher drug content as compared to the cocoa butter formulation. The optimized formulation F2 represented the optimized release of 81.35% over the range of 1 h. A little difference in drug content (1.78%), breaking strength (0.2 Kg/cm²), and disintegrating time (0.6 min) was observed in the accelerated stability study. The study concluded that MO has a noteworthy effect on drug release. The study emphasized the application of MO for release modification in suppositories since it is a non-toxic, chemically inert, economic, wide availability, and biodegradable component.